![]() |
市場調查報告書
商品編碼
1828105
2025年全球顯影劑注射器市場報告Contrast Media Injectors Global Market Report 2025 |
近年來,顯影劑注射器市場呈現強勁成長勢頭,市場規模從2024年的16.8億美元成長至2025年的17.7億美元,複合年成長率達5.7%。預測期內的成長主要受多種因素驅動,例如慢性病盛行率的上升、診斷影像程序數量的增加、對微創手術的需求、醫療基礎設施的擴展以及人口老化。
預計未來幾年顯影劑注射器市場將強勁成長,到2029年將達到24.9億美元,複合年成長率為8.9%。預測期內的成長歸因於介入性放射學手術的興起、癌症盛行率的上升、對病人安全和舒適度的重視、醫療服務的全球化以及法規支持和合規性。預測期內的主要趨勢包括自動化和連結性、雙頭注射器的出現、注射器技術的進步、對病人安全的重視、介入放射學手術的興起以及成像技術和模式的改進。
顯影劑注射器是一種先進的醫療設備,旨在注射顯影劑以增強醫學影像處理中的組織可見性,確保卓越的精確度和準確度,從而獲得最佳的手術效果。
顯影劑注射器市場的關鍵產品包括耗材、注射器系統和配件。耗材,即醫用注射器,在防止破損和洩漏、防止潛在傷害、注射器停機以及其他不良事件方面發揮著至關重要的作用。這些注射器對於安全、無耗材的診斷成像至關重要。市場提供各種類型的注射器,包括單頭注射器、雙頭注射器和無針頭注射器,專為放射學、介入性心臟病學和介入放射學應用而設計。它們廣泛應用於醫院、診斷中心和門診手術中心,滿足醫療專業人員的多樣化需求,並有助於提高診斷影像的準確性和診斷能力。
2025年春季美國關稅大幅上調及其引發的貿易摩擦對醫療設備產業產生了重大影響,尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制價格上漲,製造商面臨利潤壓力。監管挑戰進一步加劇了形勢,因為由於關稅而更換供應商通常需要醫療設備重新認證,導致市場進入延遲。為此,企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。
本研究報告是商業研究公司新報告系列的一部分,該系列提供顯影劑市場統計數據,包括全球市場規模、區域佔有率、顯影劑市場佔有率的競爭對手、詳細的顯影劑細分市場、市場趨勢和商業機會,以及在顯影劑顯影劑取得成功所需的數據。這份顯影劑市場研究報告對行業當前和未來情況進行了詳細分析,為您提供所需的一切的完整觀點。
未來五年8.9%的預測成長率,較我們先前對該市場的預測略有下降,下降了0.2%。下降的主要原因是美國與其他國家之間關稅的影響。這一影響將直接影響美國,導致來自奧地利和丹麥等主要地區的精密注射式幫浦和一次性壓力管的供應鏈中斷,可能導致影像處理檢查延誤和放射學成本上升。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響,這種影響將更加廣泛。
顯影劑注射器市場的預期成長是由癌症和心血管疾病 (CVD) 日益成長的盛行率所推動的。以不受控制的細胞生長和增殖為特徵的癌症和影響心臟和血管的 CVD 是市場的主要驅動力。顯影劑在診斷影像、改善影像品質、病患安全以及血流和組織灌注方面發揮關鍵作用。值得注意的是,美國癌症協會的統計數據顯示,癌症病例數將從 2021 年的 1,898,160 例增加 3.16% 到 2023 年 1 月的 1,958,310 例。此外,世界心臟聯盟報告稱,到 2023 年 4 月,全球將有超過 5 億人患心血管疾病,2021 年死亡人數將達到 2,050 萬,佔全球死亡總數的近三分之一。癌症和心血管疾病患者數量的快速成長是顯影劑注射器市場的主要驅動力。
預計未來對非侵入性診斷程序不斷成長的需求將推動顯影劑注射器市場的成長。非侵入性診斷程序是一種不需要透過天然或人工孔口進入體內或涉及皮膚穿透的醫學檢查或治療。顯影劑在非侵入性診斷程序中起著關鍵作用,特別是在電腦斷層掃描 (CT) 和磁振造影(MRI) 等影像方式中。例如,根據英國國民醫療服務體系 (NHS) 2023 年 5 月的數據,2023 年 1 月最常用的成像方式是普通放射線照相 (X光),共進行了 165 萬次,其次是診斷性超音波(超音波),共進行了 810,000 次,磁振造影斷層掃描 (CT) 掃描,共進行了310,000 次。因此,對非侵入性診斷程序不斷成長的需求正在推動顯影劑注射器市場的成長。
策略聯盟是顯影劑注射器市場的一大趨勢。該領域的主要企業正在積極合作,以建立新的合作關係,尤其是在類似產品開發方面。例如,比利時先進劑量和造影管理軟體解決方案提供商 Qaelum NV 與法國手術器械製造商和經銷商Ulrich GmbH & Company KG 之間的合作。透過整合資源,兩家公司旨在將 Qaelum NV 的先進顯影劑管理解決方案與 Ulrich Medical 的顯影劑相結合,以滿足醫院和診斷影像網路的需求。這種夥伴關係模式反映了業界致力於加強合作、實現互利共贏的決心。
顯影劑注射器市場的主要參與企業正專注於開發創新產品,例如非專利顯影劑劑注射器。這些含有顯影劑的藥物在增強電腦斷層掃描和 MRI 等醫學影像過程中的可視性方面發揮著至關重要的作用。值得注意的是,總部位於德國的製藥公司費森尤斯卡比 (Fresenius Kabi) 於 2023 年 8 月推出了兩種新藥。第一種是钆布醇注射液,是一種專為 MRI 設計的钆基顯影劑,擴展了費森尤斯卡比的放射學產品組合。第二種是普樂沙福注射液,是一種造血幹細胞動員劑,是費森尤斯卡比廣泛的可注射癌症治療非專利系列的補充。這種對策略產品創新的關注凸顯了該產業對競爭和擴大基本客群的承諾。
2022年11月,美國知名製造公司GE醫療科技集團與Ulrich GmbH & Co. KG達成夥伴關係。此次合作的主要目標是將多劑量顯影劑引入美國市場,並加強CT運動注射器的銷售。 Ulrich GmbH & Co. KG總部位於法國,專門從事脊椎系統和顯影劑注射器的開發、製造和銷售。此次合作體現了GE醫療科技集團的策略方針,即透過利用合作夥伴的專業知識來擴大其市場佔有率並增強其產品供應,尤其是在顯影劑注射器領域。
顯影劑市場的主要企業包括 Bracco Group、Bayer AG、Medtron AG、Ulrich GmbH And Co.KG、通用電氣公司、Nemoto Kyorindo Co. Ltd.、Guerbet Group、Sino Medical-Device Technology Co. Ltd、Apollo RT Co.Ltd、深圳安科高科技股份有限公司、Vivid ITic、Thio. Co.Ltd.、Medtronic Plc、ACIST Medical Systems、波士頓科學公司、Mallinckrodt Pharmaceuticals、Lantheus Medical Imaging Inc. 和 Imaxeon Pty Ltd。
2024年,北美是顯影劑注射器市場最大的地區。根據全球顯影劑市場報告,預計亞太地區在預測期內將成為成長最快的地區。顯影劑注射器市場報告涵蓋以下地區:亞太地區、西歐、中歐和東歐、北美、南美以及中東和非洲。
顯影劑市場報告涵蓋的國家:澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國、美國、加拿大、義大利、西班牙
顯影劑注射器市場包括 Empower CTA+、液壓磁振造影注射器、電腦斷層掃描 (CT) 注射器和注射器設備的銷售。此市場的價值是指“出廠價”,即商品製造商或生產商向其他營業單位(包括下游製造商、批發商、經銷商和零售商)或直接向最終客戶銷售的商品價值。該市場的商品價值還包括商品製造商提供的任何相關服務。
Contrast media injectors are advanced medical devices designed for administering contrast media to enhance tissue visibility in medical imaging procedures, ensuring superior accuracy and precision for optimal surgical outcomes.
The primary offerings in the contrast media injectors market include consumables, injector systems, and accessories. Consumables, also known as medical injectors, play a pivotal role in safeguarding against breaks or leaks that could lead to potential harm, injector downtime, or other undesirable incidents. These injectors are integral for conducting safe and consumable imaging procedures in diagnostics. The market features various types of injectors, including single head injectors, dual-head injectors, and syringeless injectors, tailored for applications in radiology, interventional cardiology, and interventional radiology. They find widespread usage in hospitals, diagnostics centers, and ambulatory surgery centers, catering to the diverse needs of medical professionals and contributing to the advancement of imaging precision and diagnostic capabilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The contrast media injectors market research report is one of a series of new reports from The Business Research Company that provides contrast media injectors market statistics, including contrast media injectors industry global market size, regional shares, competitors with a contrast media injectors market share, detailed contrast media injectors market segments, market trends and opportunities, and any further data you may need to thrive in the contrast media injectors industry. This contrast media injectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The contrast media injectors market size has grown strongly in recent years. It will grow from $1.68 billion in 2024 to $1.77 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increased incidence of chronic diseases, increased diagnostic imaging procedures, demand for minimally invasive procedures, expansion of healthcare infrastructure, growing aging population.
The contrast media injectors market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to rise in interventional radiology procedures, increasing prevalence of cancer, focus on patient safety and comfort, globalization of healthcare services, regulatory support and compliance. Major trends in the forecast period include automation and connectivity, emergence of dual-head injectors, advancements in injector technology, focus on patient safety, rise in interventional radiology procedures, enhanced imaging techniques and modalities.
The forecast of 8.9% growth over the next five years reflects a modest reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for precision syringe pumps and disposable pressure tubing, sourced from key regions such as Austria and Denmark, which could lead to imaging procedure delays and increased radiology department expenses.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated growth of the contrast media injectors market is set to be propelled by the increasing incidence of cancer and cardiovascular diseases (CVD). Cancer, characterized by uncontrolled cell growth and dissemination, and CVD, impacting the heart or blood vessels, are driving factors for the market. Contrast media injectors play a crucial role in diagnostic imaging, enhancing image quality, ensuring patient safety, and improving blood flow and tissue perfusion. Notably, statistics from the American Cancer Society reveal a 3.16% growth in cancer cases from 1,898,160 in 2021 to 1,958,310 in January 2023. Additionally, the World Heart Federation reports that over 500 million individuals globally will be affected by cardiovascular diseases in April 2023, leading to 20.5 million fatalities in 2021, constituting nearly one-third of total global mortality. This surge in cancer and CVD cases is a significant driver for the contrast media injectors market.
The increasing demand for non-invasive diagnostic procedures is anticipated to drive the growth of the contrast media injectors market in the future. Non-invasive diagnostic procedures are medical examinations or treatments that do not require physical entry into the body through natural or artificial openings or involve skin penetration. Contrast media injectors play a crucial role in non-invasive diagnostic methods, particularly in imaging techniques such as computed tomography (CT) scans and magnetic resonance imaging (MRI). For example, in May 2023, the National Health Service (NHS) England reported that in January 2023, plain radiography (X-ray) was the most frequently used imaging technique, with 1.65 million procedures performed. This was followed by diagnostic ultrasonography (Ultrasound) at 0.81 million, computerized axial tomography (CT scan) at 0.52 million, and magnetic resonance imaging (MRI) at 0.31 million. Therefore, the growing demand for non-invasive diagnostic procedures is propelling the growth of the contrast media injectors market.
Strategic partnerships are emerging as a prominent trend within the contrast media injectors market. Major companies in this sector are actively engaging in collaborations to foster new relationships, particularly those involving similar product developments. An illustrative example is the collaboration between Qaelum NV, a Belgium-based provider of advanced dose and contrast management software solutions, and Ulrich GmbH & Company KG, a France-based surgical instruments manufacturer and distributor. By pooling their resources, these companies aim to integrate Qaelum NV's advanced contrast management solution with Ulrich Medical's contrast media injectors, thereby addressing the requirements of hospitals and imaging networks. This partnership model demonstrates the industry's commitment to enhancing collaborative efforts for mutual benefit.
Key players in the contrast media injector market are directing their efforts towards the development of innovative products, such as generic contrast media injectables. These pharmaceutical products, containing contrast agents, play a pivotal role in enhancing visibility during medical imaging procedures such as CT scans and MRIs. Notably, Fresenius Kabi, a Germany-based pharmaceutical company, introduced two novel drugs in August 2023. The first, Gadobutrol Injection, is a gadolinium-based contrast agent tailored for MRI use, expanding Fresenius Kabi's radiology portfolio. The second, Plerixafor Injection, serves as a hematopoietic stem cell mobilizer, complementing the company's extensive collection of generic injectable oncology medicines. This strategic focus on product innovation underscores the industry's commitment to gaining a competitive edge and broadening its customer base.
In November 2022, GE HealthCare Technologies Inc., a prominent US-based manufacturing company, entered into a partnership with Ulrich GmbH & Co. KG. The primary objective of this collaboration is to introduce multi-dose contrast media injectors in the U.S. market and bolster the sales of CT motion injectors. Ulrich GmbH & Co. KG., based in France, specializes in the development, production, and distribution of spinal systems and contrast medium injectors. This collaboration exemplifies GE HealthCare Technologies Inc.'s strategic approach to expanding its market presence and leveraging the expertise of partners to enhance its product offerings, particularly in the realm of contrast media injectors.
Major companies operating in the contrast media injectors market include The Bracco Group, Bayer AG, Medtron AG, Ulrich GmbH And Co. KG, General Electric Company, Nemoto Kyorindo Co. Ltd., Guerbet Group, Sino Medical-Device Technology Co. Ltd, Apollo RT Co.Ltd, Shenzhen Anke High-tech Co. Ltd, Vivid Imaging, AngioDynamics. Inc., Medrad Inc., TaeWoong Medical Co. Ltd., Medtronic Plc, ACIST Medical Systems, Boston Scientific Corporation, Mallinckrodt Pharmaceuticals, Lantheus Medical Imaging Inc., Imaxeon Pty Ltd.
North America was the largest region in the contrast media injectors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global contrast media injectors market report during the forecast period. The regions covered in the contrast media injectors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the contrast media injectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The contrast media injectors market consists of sales of empower CTA+, hydraulic-powered MR injectors, computed tomography (CT) injectors, and syringe devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Contrast Media Injectors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on contrast media injectors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for contrast media injectors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The contrast media injectors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.